Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Greasley

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Journal of Clinical Pharmacology|October 17, 2021
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling AnalysisHongtao Yu, Sanchita Basu, Weifeng Tang, et al.
BMC Nephrology|June 23, 2018
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitusAlan S Go, Jingrong Yang, Thida C Tan, et al.
Kidney360|April 4, 2022
Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to ImmunosuppressionBenjamin M Forster, Robert Nee, Dustin J Little, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivoLauren S Whyte, Erik Ryberg, Natalie A Sims, et al.
Journal of Cardiac Failure|July 21, 2021
The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart FailurePetter Bjornstad, Peter J Greasley, David C Wheeler, et al.
Data in Brief|July 14, 2021
Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baselineBergur V Stefánsson, Hiddo J L Heerspink, David C Wheeler, et al.
Plos One|June 21, 2022
Bilirubin levels and kidney function decline: An analysis of clinical trial and real world dataYasunori Aoki, Claudia S Cabrera, Mario Ouwens, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 18, 2020
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology ModelingVictor Sokolov, Tatiana Yakovleva, Lulu Chu, et al.
Journal of Diabetes and Its Complications|September 19, 2020
Correction of anemia by dapagliflozin in patients with type 2 diabetesBergur V Stefánsson, Hiddo J L Heerspink, David C Wheeler, et al.
Frontiers in Pharmacology|October 15, 2025
Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease, primary sclerosing cholangitisRhoda E Kuc, Anna L Paterson, Thomas L Williams, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Journal of Clinical Pharmacology|October 17, 2021
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling AnalysisHongtao Yu, Sanchita Basu, Weifeng Tang, et al.
BMC Nephrology|June 23, 2018
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitusAlan S Go, Jingrong Yang, Thida C Tan, et al.
Kidney360|April 4, 2022
Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to ImmunosuppressionBenjamin M Forster, Robert Nee, Dustin J Little, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivoLauren S Whyte, Erik Ryberg, Natalie A Sims, et al.
Journal of Cardiac Failure|July 21, 2021
The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart FailurePetter Bjornstad, Peter J Greasley, David C Wheeler, et al.
Data in Brief|July 14, 2021
Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baselineBergur V Stefánsson, Hiddo J L Heerspink, David C Wheeler, et al.
Plos One|June 21, 2022
Bilirubin levels and kidney function decline: An analysis of clinical trial and real world dataYasunori Aoki, Claudia S Cabrera, Mario Ouwens, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 18, 2020
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology ModelingVictor Sokolov, Tatiana Yakovleva, Lulu Chu, et al.
Journal of Diabetes and Its Complications|September 19, 2020
Correction of anemia by dapagliflozin in patients with type 2 diabetesBergur V Stefánsson, Hiddo J L Heerspink, David C Wheeler, et al.
Frontiers in Pharmacology|October 15, 2025
Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease, primary sclerosing cholangitisRhoda E Kuc, Anna L Paterson, Thomas L Williams, et al.
Pageof 9